Hitting KRAS When It's Down.

Abstract excerpt

KRAS, one of the most prevalent oncogenes and sought-after anticancer targets, has eluded chemists for decades until an irreversible covalent strategy targeting a specific mutation (G12C) paved the way for the first KRAS inhibitors to reach the clinic. MRTX849 is one such clinical candidate with promising initial results in patients harboring the mutation. The impressive optimization story of MRTX849 highlights...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Enzyme Inhibitors
• Share to Molecular Targeted Therapy
• Share to Mutation